To date, siRNA-mediated knockdown strategies targeting PVT1 have demonstrated its role in cisplatin sensitivity in malignant pleural mesothelioma [25] and gastric cancer cells [26]. This evidence concerns the gene PVT1 and malignant pleural mesothelioma.